TAC Not Superior to AC→T for Adjuvant Treatment of Node-positive Breast Cancer

Share this content:
Docetaxel, doxorubicin, and cyclophosphamide was not superior in the treatment of node-positive breast cancer.
Docetaxel, doxorubicin, and cyclophosphamide was not superior in the treatment of node-positive breast cancer.

Docetaxel, doxorubicin, and cyclophosphamide (TAC) was not superior to doxorubicin and cyclophosphamide followed by docetaxel (AC→T) in the treatment of node-positive breast cancer, according to an article published in Annals of Oncology.1

In order to determine the optimal regimen for adjuvant breast cancer chemotherapy for women with node-positive non-metastatic breast cancer, investigators compared sequential to concurrent combination of doxorubicin and cyclophosphamide with docetaxel.

A total of 3298 women with HER2 non-amplified breast cancer were randomized to receive either doxorubicin and cyclophosphamide every 3 weeks for 4 cycles followed by AC→T every 3 weeks for 4 cycles or TAC every 3 weeks for 6 cycles. They also received standard radiotherapy and endocrine therapy and were followed for 10 years with annual clinical evaluation and mammography.

Results showed that the 10-year disease-free survival rates were 66.5% in the AC→T arm vs 66.3% in the TAC arm (P = .749). Overall survival was 79.9% in the AC→T arm vs 78.9% in the TAC arm (P = .506).

RELATED: Early MRI-based Screening May Reduce Breast Cancer Mortality Among Lymphoma Survivors

In regard to safety, TAC was linked with higher rates of febrile neutropenia; however primary prophylaxis with granulocyte- colony stimulating factor significantly reduced the risk. AC→T was linked with a higher rate of myalgia, hand-foot syndrome, fluid retention, and sensory neuropathy.

The authors concluded that the TAC regimen with prophylactic support provided shorter adjuvant treatment duration with less toxicity.

Reference

  1. Mackey JR, Pieńkowski T, Crown J, et al. Long-term outcomes after adjuvant treatment of sequential versus combination docetaxel with doxorubicin and cyclophosphamide in node-positive breast cancer – BCIRG-005 randomized trial [published online ahead of print March 2, 2016]. Ann Oncol. doi: 10.1093/annonc/mdw098.  

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters